Bolt Current Deferred Revenue vs Net Receivables Analysis

BOLT Stock

USD 0.76 0.00 0.00%

Bolt Biotherapeutics financial indicator trend analysis is way more than just evaluating Bolt Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bolt Biotherapeutics is a good investment. Please check the relationship between Bolt Biotherapeutics Current Deferred Revenue and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Current Deferred Revenue vs Net Receivables

Current Deferred Revenue vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bolt Biotherapeutics Current Deferred Revenue account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Bolt Biotherapeutics' Current Deferred Revenue and Net Receivables is 0.51. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Bolt Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Bolt Biotherapeutics' Current Deferred Revenue and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Bolt Biotherapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Current Deferred Revenue i.e., Bolt Biotherapeutics' Current Deferred Revenue and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.51

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Receivables

Most indicators from Bolt Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bolt Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.Selling General Administrative is likely to drop to about 14.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 276.4 K in 2024

	2021	2022	2023	2024 (projected)
Interest Income	281K	2.2M	6.2M	6.5M
Net Interest Income	281K	2.2M	6.2M	6.5M

Interest Income Net Interest Income

Bolt Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.94	0.93	0.94	0.93	0.91	0.9	0.94	0.68	-0.81	0.95	0.22	0.98	0.76	0.38	0.99	0.78	-0.02	0.94	0.87	0.76	0.2	0.93	0.92	0.99	-0.1
Short Long Term Debt Total	0.94		0.97	0.99	0.78	0.9	0.82	1.0	0.76	-0.89	0.99	0.18	0.91	0.85	0.46	0.93	0.94	0.23	1.0	0.94	0.77	0.44	0.78	0.99	0.94	0.08
Other Current Liab	0.93	0.97		0.99	0.81	0.92	0.84	0.97	0.87	-0.93	0.96	-0.05	0.87	0.86	0.43	0.94	0.86	0.1	0.97	0.95	0.83	0.32	0.81	0.97	0.94	0.06
Total Current Liabilities	0.94	0.99	0.99		0.8	0.92	0.83	0.99	0.82	-0.92	0.99	0.08	0.89	0.86	0.44	0.94	0.91	0.17	0.99	0.95	0.81	0.39	0.8	0.99	0.94	0.07
Total Stockholder Equity	0.93	0.78	0.81	0.8		0.86	0.93	0.77	0.55	-0.7	0.83	0.2	0.89	0.52	0.1	0.94	0.53	-0.37	0.78	0.68	0.77	-0.16	1.0	0.77	0.94	-0.4
Other Liab	0.91	0.9	0.92	0.92	0.86		0.97	0.89	0.8	-0.96	0.92	0.06	0.87	0.7	0.11	0.91	0.77	-0.11	0.9	0.81	0.96	0.1	0.86	0.91	0.91	-0.19
Net Tangible Assets	0.9	0.82	0.84	0.83	0.93	0.97		0.8	0.67	-0.86	0.85	0.12	0.87	0.56	-0.02	0.9	0.61	-0.32	0.82	0.69	0.93	-0.12	0.93	0.82	0.9	-0.38
Property Plant And Equipment Net	0.94	1.0	0.97	0.99	0.77	0.89	0.8		0.79	-0.89	0.98	0.13	0.92	0.89	0.51	0.93	0.94	0.25	1.0	0.96	0.75	0.46	0.77	0.99	0.94	0.14
Net Debt	0.68	0.76	0.87	0.82	0.55	0.8	0.67	0.79		-0.89	0.73	-0.48	0.63	0.87	0.4	0.7	0.7	0.17	0.76	0.85	0.79	0.34	0.55	0.8	0.7	0.29
Retained Earnings	-0.81	-0.89	-0.93	-0.92	-0.7	-0.96	-0.86	-0.89	-0.89		-0.89	0.1	-0.76	-0.77	-0.17	-0.82	-0.82	-0.05	-0.89	-0.83	-0.94	-0.25	-0.7	-0.92	-0.82	0.02
Accounts Payable	0.95	0.99	0.96	0.99	0.83	0.92	0.85	0.98	0.73	-0.89		0.23	0.91	0.79	0.38	0.96	0.91	0.13	0.99	0.92	0.79	0.34	0.83	0.98	0.96	-0.04
Cash	0.22	0.18	-0.05	0.08	0.2	0.06	0.12	0.13	-0.48	0.1	0.23		0.27	-0.19	-0.09	0.19	0.21	0.04	0.18	-0.04	-0.11	0.06	0.2	0.1	0.18	-0.38
Non Current Assets Total	0.98	0.91	0.87	0.89	0.89	0.87	0.87	0.92	0.63	-0.76	0.91	0.27		0.76	0.4	0.94	0.77	0.04	0.91	0.82	0.7	0.25	0.89	0.9	0.94	-0.03
Non Currrent Assets Other	0.76	0.85	0.86	0.86	0.52	0.7	0.56	0.89	0.87	-0.77	0.79	-0.19	0.76		0.75	0.74	0.85	0.5	0.85	0.93	0.56	0.67	0.52	0.87	0.74	0.54
Other Assets	0.38	0.46	0.43	0.44	0.1	0.11	-0.02	0.51	0.4	-0.17	0.38	-0.09	0.4	0.75		0.35	0.54	0.75	0.46	0.65	-0.1	0.81	0.1	0.45	0.36	0.79
Cash And Short Term Investments	0.99	0.93	0.94	0.94	0.94	0.91	0.9	0.93	0.7	-0.82	0.96	0.19	0.94	0.74	0.35		0.77	-0.06	0.93	0.88	0.78	0.16	0.94	0.92	1.0	-0.15
Common Stock Shares Outstanding	0.78	0.94	0.86	0.91	0.53	0.77	0.61	0.94	0.7	-0.82	0.91	0.21	0.77	0.85	0.54	0.77		0.51	0.94	0.89	0.62	0.68	0.53	0.93	0.77	0.29
Non Current Liabilities Total	-0.02	0.23	0.1	0.17	-0.37	-0.11	-0.32	0.25	0.17	-0.05	0.13	0.04	0.04	0.5	0.75	-0.06	0.51		0.23	0.34	-0.26	0.97	-0.37	0.22	-0.05	0.87
Capital Lease Obligations	0.94	1.0	0.97	0.99	0.78	0.9	0.82	1.0	0.76	-0.89	0.99	0.18	0.91	0.85	0.46	0.93	0.94	0.23		0.94	0.77	0.44	0.78	0.99	0.94	0.08
Other Current Assets	0.87	0.94	0.95	0.95	0.68	0.81	0.69	0.96	0.85	-0.83	0.92	-0.04	0.82	0.93	0.65	0.88	0.89	0.34	0.94		0.67	0.53	0.68	0.93	0.89	0.27
Other Stockholder Equity	0.76	0.77	0.83	0.81	0.77	0.96	0.93	0.75	0.79	-0.94	0.79	-0.11	0.7	0.56	-0.1	0.78	0.62	-0.26	0.77	0.67		-0.07	0.77	0.79	0.78	-0.3
Total Liab	0.2	0.44	0.32	0.39	-0.16	0.1	-0.12	0.46	0.34	-0.25	0.34	0.06	0.25	0.67	0.81	0.16	0.68	0.97	0.44	0.53	-0.07		-0.16	0.44	0.17	0.83
Net Invested Capital	0.93	0.78	0.81	0.8	1.0	0.86	0.93	0.77	0.55	-0.7	0.83	0.2	0.89	0.52	0.1	0.94	0.53	-0.37	0.78	0.68	0.77	-0.16		0.77	0.94	-0.4
Property Plant And Equipment Gross	0.92	0.99	0.97	0.99	0.77	0.91	0.82	0.99	0.8	-0.92	0.98	0.1	0.9	0.87	0.45	0.92	0.93	0.22	0.99	0.93	0.79	0.44	0.77		0.92	0.11
Total Current Assets	0.99	0.94	0.94	0.94	0.94	0.91	0.9	0.94	0.7	-0.82	0.96	0.18	0.94	0.74	0.36	1.0	0.77	-0.05	0.94	0.89	0.78	0.17	0.94	0.92		-0.14
Non Current Liabilities Other	-0.1	0.08	0.06	0.07	-0.4	-0.19	-0.38	0.14	0.29	0.02	-0.04	-0.38	-0.03	0.54	0.79	-0.15	0.29	0.87	0.08	0.27	-0.3	0.83	-0.4	0.11	-0.14

Click cells to compare fundamentals

Bolt Biotherapeutics Account Relationship Matchups

Bolt Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	48.4M	46.5M	307.7M	227.8M	159.8M	147.8M
Short Long Term Debt Total	10.2M	10.9M	24.4M	22.6M	20.2M	16.2M
Other Current Liab	2.9M	6.7M	12.4M	15.1M	12.5M	9.4M
Total Current Liabilities	8.7M	11.3M	21.3M	23.1M	20.5M	16.1M
Total Stockholder Equity	(45.8M)	(104.9M)	250.1M	171.5M	112.7M	67.4M
Other Liab	1.0M	329K	14.4M	13.0M	14.9M	15.7M
Net Tangible Assets	(45.8M)	(104.9M)	250.1M	171.5M	197.2M	207.1M
Property Plant And Equipment Net	11.5M	16.4M	30.6M	28.5M	24.1M	20.6M
Net Debt	(24.6M)	5.3M	(3.0M)	13.4M	9.4M	9.9M
Retained Earnings	(47.7M)	(108.4M)	(207.0M)	(295.1M)	(364.3M)	(346.1M)
Accounts Payable	2.1M	1.6M	3.6M	3.6M	3.0M	2.7M
Cash	34.8M	5.5M	27.4M	9.2M	10.8M	13.5M
Non Current Assets Total	12.5M	21.2M	118.6M	55.1M	54.3M	48.3M
Non Currrent Assets Other	446K	3.2M	2.6M	2.6M	2.0M	2.1M
Other Assets	1.0M	4.8M	2.6M	2.6M	1.0	0.95
Cash And Short Term Investments	34.8M	22.8M	186.2M	168.9M	102.2M	96.9M
Common Stock Shares Outstanding	35.1M	36.2M	37.4M	37.4M	37.8M	35.4M
Liabilities And Stockholders Equity	48.4M	46.5M	307.7M	227.8M	159.8M	147.8M
Non Current Liabilities Total	85.6M	140.2M	36.3M	33.2M	26.6M	46.8M
Capital Lease Obligations	10.2M	10.9M	24.4M	22.6M	20.2M	16.2M
Other Current Assets	1.1M	2.5M	2.9M	3.9M	2.0M	2.4M
Other Stockholder Equity	(75.7M)	(101.8M)	149.7M	239.7M	317.2M	333.1M
Total Liab	94.3M	151.5M	57.6M	56.3M	47.0M	58.5M
Net Invested Capital	(45.8M)	(104.9M)	250.1M	171.5M	112.7M	67.4M
Property Plant And Equipment Gross	11.5M	16.4M	30.6M	28.5M	29.8M	21.7M
Total Current Assets	35.9M	25.4M	189.2M	172.7M	105.5M	99.5M
Non Current Liabilities Other	71K	25.6M	210K	42K	43K	40.9K
Net Working Capital	27.2M	14.1M	167.8M	149.6M	85.3M	83.5M
Short Term Debt	3.1M	1.5M	2.5M	2.4M	2.8M	2.3M
Property Plant Equipment	11.5M	16.4M	30.6M	28.5M	32.8M	19.5M

Pair Trading with Bolt Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bolt Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bolt Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Bolt Stock

0.54

VALN

Valneva SE ADR

Pair Corr

The ability to find closely correlated positions to Bolt Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bolt Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bolt Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bolt Biotherapeutics to buy it.

The correlation of Bolt Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bolt Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bolt Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bolt Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bolt Biotherapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Bolt Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Bolt Biotherapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Bolt Biotherapeutics Stock:

How To Invest In Bolt

Details

Is Bolt Stock a good investment?

Details

What is Bolt Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bolt Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Bolt Stock analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Stocks Directory Find actively traded stocks across global markets
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Is Bolt Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bolt Biotherapeutics. If investors know Bolt will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bolt Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.66)

Revenue Per Share

0.299

Quarterly Revenue Growth

1.888

Return On Assets

(0.27)

Return On Equity

(0.48)

The market value of Bolt Biotherapeutics is measured differently than its book value, which is the value of Bolt that is recorded on the company's balance sheet. Investors also form their own opinion of Bolt Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bolt Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bolt Biotherapeutics' market value can be influenced by many factors that don't directly affect Bolt Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bolt Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bolt Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bolt Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bolt Current Deferred Revenue vs Net Receivables Analysis

Current Deferred Revenue vs Net Receivables

Current Deferred Revenue vs Net Receivables Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Receivables

Bolt Biotherapeutics fundamental ratios Correlations

Bolt Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bolt Biotherapeutics fundamental ratios Accounts

Pair Trading with Bolt Biotherapeutics

Moving against Bolt Stock

Complementary Tools for Bolt Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets

Retained Earnings	- 0.96	Other Liab
Other Stockholder Equity	- 0.94	Retained Earnings
Retained Earnings	- 0.93	Other Current Liab
Property Plant And Equipment Gross	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Total Current Liabilities
Capital Lease Obligations	- 0.89	Retained Earnings